Dabigatran versus warfarin in patients with atrial fibrillation.

  title={Dabigatran versus warfarin in patients with atrial fibrillation.},
  author={Stuart J Connolly and Michael D. Ezekowitz and Salim Yusuf and John William Eikelboom and Jonas Oldgren and Amit Parekh and Janice Pogue and Paul A. Reilly and Ellison Themeles and Jeanne Varrone and Susan Wang and Marco Alings and Denis Xavier and Jun Zhu and Rafael Diaz and Basil S. Lewis and Harald Darius and Hans Christoph Diener and Campbell D. Joyner and Lars Wallentin},
  journal={The New England journal of medicine},
  volume={361 12},
BACKGROUND Warfarin reduces the risk of stroke in patients with atrial fibrillation but increases the risk of hemorrhage and is difficult to use. Dabigatran is a new oral direct thrombin inhibitor. METHODS In this noninferiority trial, we randomly assigned 18,113 patients who had atrial fibrillation and a risk of stroke to receive, in a blinded fashion, fixed doses of dabigatran--110 mg or 150 mg twice daily--or, in an unblinded fashion, adjusted-dose warfarin. The median duration of the… 

Figures and Tables from this paper

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism and there was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivroxaban group.

Apixaban versus warfarin in patients with atrial fibrillation.

In patients with atrial fibrillation, apixaban was superior to warfarin in preventing stroke or systemic embolism, caused less bleeding, and resulted in lower mortality.

A Review of Oral Anticoagulants in Patients with Atrial Fibrillation

Novel oral anticoagulants may be a suitable alternative to warfarin for different patient populations due to minimal drug interactions, lower bleeding risk, and no monitoring requirement.

Outcomes of Dabigatran and Warfarin for Atrial Fibrillation in Contemporary Practice

The incidence of thromboembolism, bleeding, and myocardial infarction associated with initiation of dabigatran or warfarin treatment in a large, real-world population with atrial fibrillation in the FDA's Sentinel program is examined.

Rivaroxaban versus Warfarin for Prevention of Thromboembolism in Bangladeshi Patients with Non-Valvular Atrial Fibrillation

Rinaroxaban have similar efficacy and better safety profile than Warfarin in patients with nonvalvular atrial fibrillation in Bangladeshi population, and may provide more consistent and predictable anticoagulant effects.

Dabigatran for stroke prevention in atrial fibrillation.

Dabigatran administered at a dose of 150 mg BID was significantly more effective in stroke prevention than warfarin and showed a similar rate of major hemorrhages, of note, both dosages resulted in an approximately 60-70% relative risk reduction of haemorrhagic stroke.

Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.

Dabigatran Found More Effective Than Warfarin for Preventing Strokes in Atrial Fibrillation Patients

Dabigatran, a vitamin K antagonist, is just as good or better than warfarin in preventing strokes in patients with atrial fibrillation, and can do so with less risk of hemorrhage, according to a major international study.

Edoxaban versus warfarin in patients with atrial fibrillation.

Both once-daily regimens of edoxaban were noninferior to warfarin with respect to the prevention of stroke or systemic embolism and were associated with significantly lower rates of bleeding and death from cardiovascular causes.

Using Dabigatran in Patients With Stroke

A number of practical issues related to the use of dabigatran in patients with stroke or cerebrovascular disease are addressed, including concerns about bleeding, the need for frequent international normalized ratio (INR) monitoring, and significant and common food and drug interactions.



Effect of clopidogrel added to aspirin in patients with atrial fibrillation.

In patients with atrial fibrillation for whom vitamin K-antagonist therapy was unsuitable, the addition of clopidogrel to aspirin reduced the risk of major vascular events, especially stroke, and increased the riskof major hemorrhage.

Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation

Rates of hemorrhage derived from younger noninception cohorts underestimate the bleeding that occurs in practice, and this finding coupled with the short-term tolerability of warfarin likely contributes to its underutilization.

Warfarin, aspirin, or both after myocardial infarction.

Warfarin, in combination with aspirin or given alone, was superior to aspirin alone in reducing the incidence of composite events after an acute myocardial infarction but was associated with a higher risk of bleeding.

Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin

Patients with AF who have high and low rates of stroke when given aspirin can be reliably identified, allowing selection of antithrombotic prophylaxis to be individualized.

Stroke prevention using the oral direct thrombin inhibitor ximelagatran inpatients with nonvalvular atrial fibrillation. Pooled analysis from the SPORTIF III ad V studies.

Fixed-dose oral ximelagatran without coagulation monitoring prevented stroke and systemic embolism as effectively as warfarin in patients with AF.

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

An updated meta-analysis of all currently available randomized trials that extends observations about the efficacy and safety of antithrombotic therapies for preventing stroke in patients who have atrial fibrillation is presented.

Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation

A meta-analysis of all currently available trials to further characterize the comparative efficacy and safety of antithrombotic therapy for the prevention of stroke in patients with atrial fibrillation is presented.